$AZRX News

Last published 5y ago

5y agoAZRXAzurRx BioPharma to Change Corporate Name to First Wave BioPharma TodayGlobeNewswireBOCA RATON, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) ("First Wave" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointesti
5y agoAZRXAzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharmaGlobeNewswireBOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("First Wave BioPharma" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for ga
5y agoAZRXAzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease IndicationsGlobeNewswireAzurRx BioPharma to be renamed "First Wave BioPharma" and trade under new NASDAQ ticker symbol, "FWBI" Three IBD clinical indications, including ulcerative colitis and Crohn's disease, added to GI therapeutic pipeline with multiple near-term inflectio
5y agoAZRXAzurRx BioPharma Announces Reverse Stock SplitGlobeNewswireBOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development in the development of targeted, non-systemic therapies f
5y agoAZRXAzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsGlobeNewswireBOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced th
5y agoAZRXAzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsGlobeNewswireReview of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned Part 2 of RESERVOIR Trial to Enroll Up to 150 Patients to Evaluate Efficacy of FW-1022 and Extend Safety Observations BOCA RATON, Fla., Sep
5y agoAZRXAzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated ColitisGlobeNewswireBOCA RATON, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal
5y agoAZRXAzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireBOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced t
5y agoADMP AZRX BPTH INDI+1Thinking about buying stock in Bio-Path Holdings, AzurRx BioPharma, Adamis Pharmaceuticals, indie Semiconductor, or Orphazyme?PR NewswireNEW YORK, Aug. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BPTH, AZRX, ADMP, INDI, and ORPH.
5y agoAZRX BWAY GRUB MVST+1Thinking about buying stock in AzurRx BioPharma, Tilray, Microvast, Brainsway, or Just Eat Takeaway?PR NewswireNEW YORK, Aug. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AZRX, TLRY, MVST, BWAY, and GRUB.
5y agoAZRXAzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)GlobeNewswireMS1819 and PERT combination therapy achieves primary and secondary outcome measure endpoints Study data indicates clinically meaningful improvement in coefficient of fat absorption (CFA) primary endpoint 20-patient study suggests combination thera
5y agoAZRXAzurRx BioPharma Announces WHO Publication of "Adrulipase Alfa" as International Nonproprietary Name for MS1819GlobeNewswireBOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced th
5y agoAZRXAzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsGlobeNewswireBOCA RATON, Fla., Aug. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today
5y agoAZRXAzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter's Option to Purchase Additional SharesGlobeNewswireBOCA RATON, Fla., July 27, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal
5y agoARDX AZRX GOTU NCLH+1Thinking about buying stock in TAL Education, Gaotu Techedu, AzurRx BioPharma, Ardelyx, or Norwegian Cruise Line?PR NewswireNEW YORK, July 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TAL, GOTU, AZRX, ARDX, and NCLH. T
5y agoAZRX CEMI GE TAL+1Thinking about buying stock in TAL Education, Chembio Diagnostics, AzurRx BioPharma, Summit Wireless Technologies, or General Electric?PR NewswireNEW YORK, July 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TAL, CEMI, AZRX, WISA, and GE. To s
5y agoAZRXAzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 MillionGlobeNewswireBOCA RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal
5y agoAZRXAzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common StockGlobeNewswireBOCA RATON, Fla., July 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal
5y agoAZRX BBBT GTVH RRSFF+2New To The Street / Newsmax TV Announces 6 Interviews For This Weeks' 199th TV Broadcast, Sunday, July 18, 2021, Hour Slot 10-11 AM ETGlobeNewswireNEW YORK, July 16, 2021 (GLOBE NEWSWIRE) -- FMW Media's New to The Street / Newsmax TV announces its TV airing of this weeks', Sunday, July 18, 2021, broadcasting line-up of its national syndicated 1- hour show, 10-11AM ET. New to The Street's 199th
5y agoAZRXAzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO DigitalGlobeNewswireBOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal
5y agoAZRXAzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsGlobeNewswire"RESERVOIR" trial to evaluate niclosamide's ability to target SARS-CoV-2 in the GI tract Topline trial data expected in Q1 2022 BOCA RATON, Fla., June 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Compan
5y agoAZRX DGDM SWISF TINO+1FMW Media, Inc.'s "New to The Street" TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ETGlobeNewswireNEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- FMW Media's "New to The Street" TV broadcasting its national syndicated 1- hour show, Sunday, May 16, 2021 on NEWSMAX TV from 10-11AM ET. "New To The Street's" TV Sunday line-up features 6 interviews o
5y agoAZRXAzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)GlobeNewswireDELRAY BEACH, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal
5y agoAZRX HIPH INND WINR+2FMW Media, Inc.'s "New to The Street" TV Announces 8 Interviews Being Broadcast on NEWSMAX TV, Sunday, May 16, 2021, Hour Slot 10-11AM ET.GlobeNewswireNEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- FMW Media's "New to The Street" TV broadcasting its national syndicated 1- hour show, Sunday, May 16, 2021 on NEWSMAX TV from 10-11AM ET. "New To The Street's" "BIG" TV Sunday line-up features the following
5y agoAZRXFMW Media's "New To The Street" Syndicated TV Show Features AzurRx BioPharma, Inc.GlobeNewswireNEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- FMW Media Corp. announces that its "New To The Street" business TV show will feature AzurRx BioPharma, Inc. (NASDAQ:AZRX) in a 3-part TV series featured across its entire syndicated linear television platform.
5y agoAZRXAzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic InsufficiencyGlobeNewswireData from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint Full top-line data expected in Q2 2021 DELRAY BEACH, Fla., May 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma,
5y agoAZRXAzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)GlobeNewswireDELRAY BEACH, Fla., May 12, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal
5y agoAZRXAzurRx BioPharma to Present at the Emerging Growth Conference (May 12)GlobeNewswireDELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal
5y agoAZRXAzurRx BioPharma to Present at Investor Summit Group's Q2 Virtual Investor Summit (May 17)GlobeNewswireDELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal
5y agoAZRX BOXL DBCCF DTII+5CEO Presenting on the Emerging Growth Conference on May 12. Register hereGlobeNewswireMIAMI, May 10, 2021 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth markets and companies, announces the Schedule of the 7th Emergi
5y agoAZRXAzurRx BioPharma CEO Issues Letter to ShareholdersGlobeNewswireDELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
5y agoAZRX PPDAzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated ColitisGlobeNewswireDELRAY BEACH, Fla., April 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
5y agoAZRX PPDAzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal InfectionsGlobeNewswire“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline data expected in Q1 2022 DELRAY BEACH, Fla., April 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma,...
5y agoAZRXAzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference CallGlobeNewswireDELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
5y agoAZRXAzurRx BioPharma to Report Topline Data from Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic FibrosisGlobeNewswireDELRAY BEACH, Fla., March 31, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
5y agoAZRXAzurRx BioPharma Announces Completion of Enrollment in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic InsufficiencyGlobeNewswireDELRAY BEACH, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
5y agoAZRXAzurRx BioPharma Announces Completion of Enrollment in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic FibrosisGlobeNewswireTop-line data expected by end of Q1 2021 DELRAY BEACH, Fla., March 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage...
5y agoAZRXAzurRx BioPharma to Present at the Maxim Group Emerging Growth Virtual Conference (March 17-18)GlobeNewswireDELRAY BEACH, Fla., March 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
5y agoAZRXAzurRx BioPharma Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireDELRAY BEACH, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
5y agoAZRXAzurRx BioPharma to Participate in the 33rd Annual Roth ConferenceGlobeNewswireDELRAY BEACH, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
5y agoAZRXAzurRx BioPharma to Participate in “Fireside Chat” at the H.C. Wainwright Global Life Sciences ConferenceGlobeNewswireDELRAY BEACH, Fla., March 02, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
5y agoAZRXAzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of DirectorsGlobeNewswireDELRAY BEACH, Fla., Feb. 24, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
5y agoAZRXAzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland ConferenceGlobeNewswireDELRAY BEACH, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
5y agoAZRXAzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal InfectionsGlobeNewswirePhase 2 Study of oral niclosamide planned for 1H 2021 DELRAY BEACH, Fla., Feb. 09, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage...
5y agoAZRXAzurRx BioPharma to Present at BIO CEO & Investor Digital ConferenceGlobeNewswireDELRAY BEACH, Fla., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
5y agoAZRXAzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819GlobeNewswireDELRAY BEACH, Fla., Jan. 28, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
5y agoAZRXAzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis PatientsGlobeNewswireDELRAY BEACH, Fla., Jan. 26, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
5y agoAZRXVivakor Installs Independent Board of DirectorsACCESS NewswireEstablishes a Stronger Company through Improved Corporate Governance
5y agoAZRXAzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis PatientsGlobeNewswireDELRAY BEACH, Fla., Jan. 21, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic,...
5y agoAZRXAzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal InfectionsGlobeNewswirePatent allowed by the USPTO that includes claims for niclosamide as a treatment for COVID-19 GI infectionsCOVID-19 GI infections are a significant unmet clinical need; AzurRx estimates potential U.S....